Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04707469) enrolled 1,606 participants across three groups, each taking a different daily dose of oral semaglutide — 14 mg, 25 mg, or 50 mg. The trial was measuring changes in blood sugar control and body weight in people with type 2 diabetes over about 52 to 68 weeks. Blood sugar control was tracked using a measure called HbA1c, which reflects average blood sugar levels over roughly three months, and fasting plasma glucose (FPG), which is a blood sugar reading taken after not eating overnight. The reported data shows that at 52 weeks, average HbA1c fell by 1.5 percentage points in the 14 mg group, 1.9 percentage points in the 25 mg group, and 2.1 percentage points in the 50 mg group, compared to where each group started. At 68 weeks, the reported reductions were similar: 1.5, 1.8, and 2.0 percentage points respectively. For fasting blood sugar, the reported average reductions at 52 weeks were 2.4 mmol/L (14 mg group), 3.0 mmol/L (25 mg group), and 3.2 mmol/L (50 mg group), with the same figures reported again at 68 weeks. The reported data also shows average body weight reductions at 52 weeks of 4.4 kg in the 14 mg group, 7.1 kg in the 25 mg group, and 8.3 kg in the 50 mg group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37385279) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Type 2 Diabetes Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You are 18 years old or older at the time of signing the consent form.
- You have been diagnosed with type 2 diabetes for at least 6 months before the screening visit.
- Your HbA1c (a blood test that measures average blood sugar levels over the past 2-3 months) is between 8.0% and 10.5%.
- Your body mass index (BMI, a measure of body weight relative to height) is 25 or above.
- You have been taking a stable dose of at least one approved diabetes medication for at least 90 days before screening — this could include metformin, sulfonylureas, SGLT2 inhibitors, or DPP-4 inhibitors (confirm with trial site for exact dose requirements).
- If you are currently taking a DPP-4 inhibitor medication for diabetes, you must be willing to stop taking it when you formally join the trial (no gradual reduction period required).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have taken any diabetes or weight-loss medications in the past 90 days that are not listed in the inclusion criteria above (though short-term insulin use for up to 14 days before screening may be acceptable).
- You have significant kidney disease, specifically a kidney function score (eGFR) below 30 mL/min/1.73 m².
- You have uncontrolled or unstable diabetes-related eye problems affecting the retina or central vision, confirmed by an eye examination within 90 days before or shortly after screening.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Clinical Transparency (dept. 1452), Novo Nordisk A/S
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 7 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Change From Baseline in Glycated Haemoglobin (HbA1c) (Week 52)
Other options
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.